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RESEARCH ARTICLE Open Access
Quality of life among injectable and oral
disease-modifying therapy users in the
Pacific Northwest Multiple Sclerosis Registry
Tamela Stuchiner1*, Lindsay Lucas1, Elizabeth Baraban1, Kateri J. Spinelli2, Chiayi Chen1, Alden Smith3,
Lobat Hashemi3 and Stanley Cohan1
Abstract
Background: Nine oral disease-modifying therapies (DMTs) have been approved for the treatment of multiple
sclerosis (MS) in the United States. Few studies have examined self-reported quality of life (QoL) and functional
status outcomes among patients who switch to oral medications from injectable MS therapies. This study compares
self-reported QoL and disability status between participants switching from injectable to oral DMTs, to those who
stay on injectable DMTs continuously for the same time period.
Methods: Longitudinal data were assessed from relapsing MS participants in the Pacific Northwest MS Registry
completing a minimum of two surveys between 2012 and 2018 with a maximum of 36 months between surveys.
Stayers were defined as those who remained on injectable DMTs continuously from Time 1 to Time 2; switchers
were those who switched from injectable to either fingolimod, teriflunomide or dimethyl fumarate during the same
time interval. Outcomes of interest were physical and psychological QoL, measured by the Multiple Sclerosis Impact
Scale (MSIS-29), and disability, measured by the Patient Determined Disease Steps (PDDS). To analyze the effect of
switching to oral DMT on outcomes at Time 2, a one-to-two propensity score matching (PSM) was used to match
switchers to stayers. Outcomes at Time 2 were analyzed using paired t-test for QoL scores, and Stuart Maxwell test
for PDDS as a categorical variable.
Results: Among 2385 participants who returned consecutive yearly surveys, 413 met the inclusion criteria for
stayers and 66 for switchers. After one-to-two PSM, 124 stayers were matched to 62 switchers. Paired t-test showed
no differences between switchers and stayers for physical (mean difference: − 0.41; [95% confidence interval CI: −
3.3-2.4]; p = 0.78) or psychological (mean difference: − 0.23; [95% CI, − 1.6- 1.1]; p = 0.74) QoL. Additionally, no
differences were seen between switchers and stayers in self-reported disability status.
Conclusions: MS registry participants who switched to an oral DMT from injectable showed no significant
differences in QoL or self-reported disability status compared to those remaining on injectable DMT continuously in
the same time period.
Keywords: Multiple sclerosis, Disease-modifying therapies, Oral DMT, Injectable DMT, Quality of life, Disability, MSIS-
29, PDDS
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Background
At the time of this study, three oral disease-modifying
therapies (DMTs) had received regulatory approval in
the US for the treatment of multiple sclerosis (MS):
fingolimod, teriflunomide, and dimethyl fumarate. Six
additional oral medications, diroximel fumarate, mono-
methyl fumarate, siponimod, cladribine, and ozanimod,
as well as a generic for dimethyl fumarate have been ap-
proved in the United States (U.S.) within the last 18
months, but were not being used by any patients in our
study population. Prior to the approval of oral DMTs,
injectable therapies, including interferon β-1a, interferon
β-1b, and glatiramer acetate, were considered first-line
medications for MS. Some patients on injectable therap-
ies may prefer switching to oral DMTs when disease ac-
tivity is not controlled, or when side effects or decline in
quality of life (QoL) prompt a desire for change. In
addition to therapeutic efficacy, oral DMTs offer signifi-
cant benefits related to ease-of-use and potentially in-
creased adherence, despite the requirement for daily
dosing [1–3].
For many people with MS, QoL declines as the disease
progresses and can be a significant burden [4]. Previous
studies have found that physical and psychological QoL
are influenced by progression of disease, level of disabil-
ity, socio-economic factors, lifestyle choices, and DMT
usage [4–6]. Few studies have examined patient reported
QoL outcomes in those who have switched to oral medi-
cations from injectable therapies; existing studies asses-
sing QoL among users of various DMTs have showed
varying results.
Due to inconsistent findings and lack of published lon-
gitudinal studies of large community cohorts, we ana-
lyzed self-reported QoL and disability status from a
longitudinal database collected from a regional commu-
nity cohort of people with MS to help assess the impact
of switching to oral from injectable DMT on QoL. The
Pacific Northwest Multiple Sclerosis Registry (PNWM
SR) was developed in 2007 with the objective of collect-
ing self-reported demographic and disease-specific infor-
mation from people with MS in the Pacific Northwest
region of the U.S. An annual survey queries participants
about access to and compliance with MS treatment op-
tions, treatment history, level of disability, comorbidities,
lifestyle, and QoL. The registry is publicized through
media, National MS Society events, web listings, neur-
ology specialty clinics, and assistance from the National
MS Society’s Oregon Chapter, and pharmaceutical com-
panies. All data are self-reported through confidential
surveys by participants who are age 18 or older, with a
diagnosis of MS. As of December 2018, 4970 individuals
with MS have registered, and 3100 are active in the
registry. Because the participants’ personal data collected
by the PNWMSR are confidential, and there is a
minimal time commitment on the part of the partici-
pants, return rates of the follow-up survey are high,
allowing us to examine self-reported aspects of this MS
population longitudinally over many years. In this study,
we used data from the PNWMSR to compare self-
reported QoL and disability status of participants who
switched from injectable to oral DMT, to those who




Participants included in the study were registered in the
PNWMSR and completed a minimum of two annual
surveys between 2012 and 2018. Questions included in-
come, education, duration and clinical pattern of MS, in-
surance, access to care, use of DMTs, medication
adherence, current symptoms, health risk behaviors, the
Patient Determined Disease Steps (PDDS) measuring
disability, and the Multiple Sclerosis Impact Scale
(MSIS-29), which assesses physical and psychological
impact of MS on QoL [7–9].
Among registered participants with relapsing MS, two
cohorts were identified: “switchers,” those who switched
from injectable DMT to oral DMT, and “stayers,” those
who stayed on injectable DMT. Stayers reported use of
an injectable DMT for a minimum of 12months at Time
1 and were on injectable DMT continuously through
Time 2. Switchers reported use of an injectable for a
minimum of 12months at Time 1 and reported use of
an oral DMT for a minimum of six months at Time 2. A
minimum of > 6 months and a maximum of 36months
between Time 1 and Time 2 surveys was required for
inclusion.
Participants who changed to infusion medication,
stopped medication use, or did not report medication
use between Time 1 and Time 2 were excluded. This
study was approved by the Providence Health & Services
Institutional Review Board.
Propensity score matching
To analyze the effect of switching to oral DMT on out-
comes at Time 2, we used propensity score matching
(PSM) to match switchers with stayers who had a similar
length of time between Time 1 and 2 surveys and who
also had similar demographic and clinical characteristics
at Time 1. The propensity scores were calculated using a
generalized linear model with a logit link. The following
matching variables were selected a priori due to their ef-
fect on outcomes in previous studies: age, sex, psycho-
logical MSIS, physical MSIS, PDDS, and health
insurance availability at Time 1 and length of time be-
tween Time 1 and 2 [10–12]. If a stayer reported to be
on an injectable for several surveys, the Time 1 and
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Time 2 surveys could be any two of their surveys as long
as they met the inclusion criteria. For matching, PDDS
at Time 1 was categorized as no or mild disability (0–1)
or moderate to severe [2–8]. The moderate [2–4] and
moderate to severe [5–8] groups were combined due to
the smaller number of participants in these groups. One
switcher was matched to two stayers without replace-
ment based on closest propensity score using a caliper
of 0.50 standard deviations. Only switchers and stayers
with non-missing matching variables and outcomes were
eligible for matching.
To determine balance between matched groups, differ-
ences in each matching covariate after PSM were calcu-
lated. Standardized mean differences of < 10% for
continuous variables and absolute mean differences of <
10% for binary variables were used to determine whether
the matched groups were balanced. Before PSM, con-
tinuous variables were compared between cohorts using
two sample t or Wilcoxon rank sum tests, as appropriate
based on normality, and categorical variables were com-
pared with chi-square tests. After PSM, comparisons
were made using paired t-tests for continuous variables,
McNemar’s tests for categorical variables with two cat-
egories, and Stuart-Maxwell test for categorical variables
with more than two categories.
Statistical analysis
Psychological MSIS and physical MSIS scores at Time 2
were compared between matched switchers and stayers
using paired t-tests, and PDDS at Time 2 was compared
using the Stuart-Maxwell test. All tests were two-tailed
with alpha equal to 0.05; p-values < 0.05 were considered
statistically significant. R 3.3.2 software (R Foundation
for Statistical Computing, Vienna, Austria) was used for
statistical analyses and graphics.
Outcomes
Three outcomes collected at Time 2 were compared be-
tween matched switchers and stayers: physical MSIS,
psychological MSIS, and PDDS. The MSIS contains 29
items, 20 related to physical impact of MS on QoL and
9 related to psychological impact. Each item represents
one indicator of the impact of MS on QoL (e.g. ability to
do physically demanding tasks, bothered by spasms or
stiffness, feeling mentally fatigued, etc.). The participant
chooses a number between 1 and 4 based on the impact
their disease has on that QoL item (1 = low impact, 4 =
high impact). Adding each participant’s score for each
test item results in a range of 20 to 80 for physical MSIS
scores and 9 to 36 for psychological MSIS scores, with
higher scores indicating a greater impact of MS on QoL.
As recommended by MSIS scoring guidelines, partici-
pants missing greater than 50% of items on either scale
were excluded from the analysis and for those missing
less than 50% of items on either scale, a respondent spe-
cific mean score was imputed from the items completed
[7]. The PDDS is an ordinal questionnaire that allows
the participant to self-classify their level of disability on
a scale of 0 to 8, with 8 being the most disabled. For this
analysis, PDDS at Time 2 was categorized as none or
mild disability (0–1), moderate disability [2–4], or mod-
erate to severe disability [5–8].
Sensitivity analysis
The PSM did not include disease duration as a matching
variable because 13% (n = 8) of switchers were missing
disease duration. However, disease duration could have
an effect on outcomes at Time 2. Therefore, we per-
formed a sensitivity analysis where disease duration was
added as a matching variable.
Results
Among 2385 PNWMSR participants who completed
at least two surveys between 2012 and 2018, 1542
participants had relapsing MS. Of these, 413 met the
inclusion criteria for a stayer and 66 met the inclu-
sion criteria for a switcher. Two switchers and 17
stayers had missing matching variables or Time 2
outcomes, leaving 396 stayers and 64 switchers eli-
gible for matching (Fig. 1).
Participant characteristics at Time 1 prior to matching
are reported in Table 1. There were no differences in
age, disease duration, or sex. There was a numerically
higher mean psychological MSIS score at Time 1 in
Switchers (17.75 [±5.72] vs 16.28 [±5.96], p = 0.067). A
significantly high number of participants in the Stayer
group were of white race (p = 0.002) and have public
health insurance (p = 0.01).
In the one-to-two PSM, 124 stayers were matched
with 62 switchers. Standardized mean differences were <
10% for continuous variables and absolute mean differ-
ences were < 10% for binary variables (Supplemental Fig-
ure 1). After matching, there were no statistically
significant differences in matching variables between
participants, however white race was higher in Stayers
and disease duration was higher in Switchers (p = 0.017
and p = 0.038 respectively) (Table 2).
Physical and psychological QoL scores for matched
participants at Time 2 are reported in Table 3. After
matching, there were no significant differences between
stayers and switchers for impact of MS on physical
(mean difference: − 0.41; [95% confidence interval, CI: −
3.3-2.4; p = 0.78] or psychological (mean difference: -0.23
[95% CI: − 1.6-1.1]; p = 0.74) QoL. PDDS at Time 2 also
showed no significant differences between switchers and
stayers after matching (Fig. 2).
Sensitivity analysis with inclusion of disease duration
as a matching variable resulted in a one-to-two PSM
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with 110 stayers with 55 switchers. Standardized mean
differences were < 11% for continuous variables and ab-
solute mean differences were < 10% for binary variables.
There were no significant differences after matching in
the sensitivity analysis in physical QoL (mean difference:
-0.70 [95% CI: − 3.8-2.4] p = 0.65), in psychological QoL
(mean difference: -1.49 [95% CI: − 3.0-0.03] p = 0.06; or
PDDS (Table 4, Fig. 3).
Discussion
Participants in the PNWMSR who stayed on injectable
DMTs reported no significant differences in physical or
psychological MSIS when compared to those who
switched to an oral DMT at Time 2 after propensity
score matching. The numeric difference in the psycho-
logical QoL at Time 2 suggests a better outcome for
switchers than stayers, although the difference did not
Fig. 1 Participant and analysis flowchart
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Table 1 Participant Characteristics before Matching
Stayer Switcher P value
396 64
Mean age (SD) 54.99 (10.34) 52.92 (12.16) 0.149
Sex % (n) Female 86.6 (343) 89.1 (57) 0.734
Male 13.4 (53) 10.9 (7)
Race % (n) White 93.7 (371) 87.5 (56) 0.002
Non-white 3.0 (12) 0.0 (0)
Unknown 3.3 (13) 12.5 (8)
Median disease duration [IQR] 12 [8, 18] 12 [7, 19] 0.839
PDDS % (n) None or mild 41.9 (166) 51.6 (33) 0.191
Moderate to severe 58.1 (230) 48.4 (31)
Work status % (n) Employed 46.3 (179) 55.6 (35) 0.217
Not Employed 53.7 (208) 44.4 (28)
Insurance % (n) Public 27.0 (107) 20.3 (13) 0.01
Private 44.2 (175) 64.1 (41)
None/Other/Not Reported 28.8 (114) 15.6 (10)
Mean MSIS Physical Score at Time 1 (SD) 33.85 (12.49) 31.69 (9.98) 0.19
Mean MSIS Psychological Score at Time 1 (SD) 16.28 (5.96) 17.75 (5.72) 0.067





[SD standard deviation, IQR Interquartile range, PDDS Patient Determined Disease Steps, MSIS Multiple Sclerosis Impact Scale]
Table 2 Participant Characteristics after Matching
Stayer Switcher P value
124 64
Mean age (SD) 52.56 (10.51) 53.18 (11.96) 0.617
Sex % (n) Female 87.9 (109) 88.7 (110) 1.000
Male 12.1 (15) 11.3 (14)
Race % (n) White 92.7 (115) 90.3 (112) 0.017
Non-white 4.0 (5) 0.0 (0)
Unknown 3.2 (4) 9.7 (12)
Median disease duration [IQR] 11 [7, 15] 12 [7, 19] 0.038
PDDS % (n) None or mild 44.4 (55) 51.6 (64) 0.306
Moderate to severe 55.6 (69) 48.4 (60)
Work status % (n) Employed 52.9 (63) 55.7 (68) 0.435
Not Employed 47.1 (56) 44.3 (54)
Insurance % (n) Public 31.5 (39) 21.0 (26) 0.114
Private 57.3 (71) 62.9 (78)
None/Other/Not Reported 11.3 (14) 16.1 (20)
Mean MSIS Physical Score at Time 1 (SD) 32.12 (11.67) 31.76 (10.09) 0.779
Mean MSIS Psychological Score at Time 1 (SD) 17.61 (6.62) 17.55 (5.66) 0.916





[SD standard deviation, IQR Interquartile range, PDDS Patient Determined Disease Steps, MSIS Multiple Sclerosis Impact Scale]
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achieve statistical significance. Given the wide confi-
dence intervals, this failure to reach statistical signifi-
cance (p = 0.06) may reflect the relatively small size of
the stayer cohort, a potential shortcoming that may be
addressed in future studies.
Additionally, no differences were seen in reported dis-
ability status between those who stayed on injectable
versus those who switched to an oral medication.
To our knowledge, this is the first longitudinal study
to provide clinicians with data on the long-term impact
of changing from an injectable to an oral medication on
MS patients’ perceived QoL and disability. While some
of the most notable reported differences between inject-
able and oral DMT have been superior adherence and
persistence to oral therapy, our survey design did not
allow us to assess adherence or persistence [1, 2, 13].
Despite previous data on better adherence for oral
DMTs, our study found no significant differences in im-
pact of switching to oral DMTs on patient self-reported
QoL and disability status.
Self-perceived disability status and physical and psy-
chological QoL can play a role in medication adherence
and persistence. McKay et al. reported that longer dis-
ease duration, mild disability status, and perceived
cognitive difficulties were all associated with non-
adherence [14]. In addition, Devonshire et al. found that
adherent patients had significantly better scores on QoL
and less psychological issues [15]. Our findings are at
odds with some previously reported studies, adding to
the knowledge base that may assist both MS patients
and their health care providers in the decision-making
process regarding medication choices.
Comparative DMT efficacy measures were not part of
our study design and were beyond the scope of this pro-
ject. Future studies should directly address the relation-
ship between medication adherence and self-reported
measures of perceived efficacy, QoL, and disability status
among oral and injectable DMT users. In addition, fu-
ture studies should include the recently U.S.-approved
oral medications cladribine, siponimod, and diroximel
fumarate, as their use becomes more widespread and of
prolonged duration.
Prior studies examining differences in QoL among
users of injectable versus oral DMT, as well as those
who switch from injectable to oral DMT, have had con-
flicting results [16–20]. The Evaluate Patient Outcomes
trial and related post hoc analyses found that patients
switching from injectable to the oral DMT fingolimod







Paired t-test P -value
Physical MSIS-29, mean (SD) 32.6 (±11.6) 32.2 (±10.9) −0.41 (−3.25, 2.43) 0.78
Psychological MSIS-29, mean (SD) 16.5 (±6.6) 16.2 (±4.9) −0.23 (−1.56, 1.11) 0.74
Fig. 2 Time 2 Disability Outcomes After Propensity Score Matching. PDDS disability scores were grouped into mild disability (0–1), moderate
disability (2–4) or moderate to severe disability (5–8). Stayers and switchers were compared in each group
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had improved patient-reported and physician-reported
outcomes at six months, including global satisfaction
with treatment, improved QoL, and decreased fatigue
and depression [16, 18, 19]. A study examining patient-
reported outcomes in relapsing MS patients switching to
teriflunomide from other DMTs found patients had sus-
tained stable QoL, using the Multiple Sclerosis Inter-
national Quality of Life (MusiQoL) [17]. In contrast, a
study comparing QoL among relapsing MS patients by
use of DMT, utilizing the Functional Assessment of
Multiple Sclerosis (FAMS) and the Expanded Disability
Status Scale (EDSS), found that there were no significant
differences between users of interferon β-1b, fingolimod,
and natalizumab [20].
Our results contribute to the literature in several ways.
First, our study was conducted using longitudinal data
from a community-based cohort, utilizing self-reported
QoL and disability. Second, although limited to partici-
pants from the Pacific Northwest, our sample was more
representative of the general MS population, and not
subject to the selection bias inherent in controlled clin-
ical trials or demographic bias when patients are re-
cruited from specific clinics or MS Centers, in that
participation was voluntary and participants were re-
cruited via multiple techniques and sources, including
local chapters of the National MS Society. This allows
for a more broadly representative sample. When com-
paring recently published average MSIS-29 values from
another registry with the ones from our registry, MSIS-
29 scores (physical) are higher in our study, while, con-
versely, MSIS-29 psychological scores are lower in our
study, highlighting variability among reported MSIS data
in published studies [21]. One potential contributor to
the seemingly low MSIS scores is that the population
was comprised of patients with the relapsing form of dis-
ease, who were receiving disease modifying therapy, thus
eliminating potentially higher scores associated with the
greater disability accompanying the progressive pheno-
type of the disease. Indeed, the relatively lower numbers
of patients with moderate [2–4] and moderate to severe
[5–8] PDDS scores in this study supports this notion.
There are several limitations of this study. First, this
was an observational rather than a randomized design
utilizing self-reported measures. However, the nature of
the design allowed our participants to be followed for up
to 36months in a real-world setting, whereas analyses







Paired t-test P -value
Physical MSIS-29, mean (SD) 33.5 (±10.7) 32.8 (±11.4) − 0.70 (− 3.77, 2.36) 0.65
Psychological MSIS-29, mean (SD) 17.7 (±6.4) 16.3 (±5.0) −1.49 (−3.01, 0.03) 0.06
Fig. 3 Time 2 Disability Outcomes After Propensity Score Matching with Sensitivity Analysis including Disease Duration as a Matching Variable.
PDDS disability scores were grouped into mild disability (0–1), moderate disability (2–4) or moderate to severe disability (5–8). Stayers and
switchers were compared in each group
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published previously have been of shorter duration and
thus provide no information on longer-term or sustained
benefits of switching to oral DMTs, or were limited to
the protocol-determined patient selection restrictions of
controlled clinical trials [16, 18, 19]. Second, there may
be potential shortcomings associated with incomplete or
missing data. To address this limitation for the physical
and psychological MSIS, participants missing greater
than 50% of items on either scale were excluded from
the analysis. For those missing less than 50% of items on
either scale, a respondent specific mean score was im-
puted from the items completed [7]. Third, the partici-
pants were from a specific geographical region and thus
results may not be generalizable to those living in other
areas, or in which greater racial or ethnic diversity is
present in the MS population. However, the design
allowed for capture of a very high percentage of patients
living within the registry catchment area. Fourth, reasons
for switching DMT were not collected. Further studies
could explore the relationship between reasons for
switching and patient outcomes. Fifth, adherence data
was not collected, thus impact of the known adherence-
related benefit of oral DMTs could not be assessed.
Lastly, three new oral agents have been approved since
the last data collection cycle, and thus their impact can-
not be reported in the current study but will be included
in future assessments.
We believe that our study provides meaningful insights
by showing a lack of impact of switching from injectable
to oral DMTs on MS participants’ self-reported QoL
and disability status, perhaps tempering what may be
overly sanguine assumptions regarding oral DMTs in
the areas with which this study is concerned. In addition,
our study supports the utility of community-based
sources of data for MS research.
Conclusions
In our large, regional, community-based MS registry,
participants making the transition from injectable to
oral DMTs showed no significant differences in self-
reported outcomes for physical and psychological
QoL and disability compared to those who stayed on
injectable DMT. As the duration and number of sub-
jects using oral DMTs for MS grows, additional out-
comes analyses that include differentiations between
the various oral agents, inclusion of more recently ap-
proved oral DMTs, higher efficacy parenteral DMTs,
adherence and discontinuation analyses, and side ef-
fect profiles will provide critically important analytic
opportunities.
Supplementary Information




95% CI: 95% confidence intervals; DMT: disease-modifying therapy;
EDSS: Expanded Disability Status Scale; FAMS: Functional Assessment of
Multiple Sclerosis; MSIS-29: Multiple Sclerosis Impact Scale; PDDS: Patient
Determined Disease Steps; PSM: propensity score matching; QoL: quality of
life
Acknowledgements
The authors would like to thank the participants of the Pacific Northwest
Multiple Sclerosis Registry and their families.
Authors’ contributions
TS: Study design, data collection, analysis, and interpretation, writing of the
manuscript, and critical review; LL: Study design, analysis and interpretation,
writing of the manuscript, and critical review; EB: Study design, data
interpretation, and editing and critical review of the manuscript; KJS: Data
interpretation, writing of the manuscript, and critical review; CC: Study
design, data interpretation, and editing and critical review of the manuscript;
AS: Study design, data interpretation, and editing and critical review of the
manuscript; LH: Study design, data interpretation, and editing and critical
review of the manuscript; SC: Study design, data interpretation, and editing
and critical review of the manuscript. The authors read and approved the
final manuscript.
Funding
This study was completed with support from Sanofi Genzyme. Editorial
support was provided by Eloquent Scientific Solutions and funded by Sanofi.
The funding sponsor was involved in the study design, and interpretation of
data, as well as verification of the data presented in the manuscript. The
authors had unrestricted access to study data, were responsible for all
content and editorial decisions, and received no honoraria related to the
development of this publication.
Availability of data and materials
The datasets generated and/or analyzed during the current study are
available in the Pacific Northwest MS Registry repository, but restrictions
apply to the availability of these data, which were used under license for the
current study, and so are not publicly available.
Ethics approval and consent to participate
This study was approved by the Providence Health & Services Institutional
Review Board. The registration form completed by participants includes
language of consent that states by submitting the registration form, consent
is given to participate in the study. In accordance with the Providence
Health & Services Review Board, implied consent was reviewed and
approved by the Privacy Board. As this is a regional, voluntary registry for
which not all participants are patients of our healthcare system and
therefore they register through the website, it is not practical to obtain
written consent for all participants. After 2014, the registry became electronic
(online only). Date of submission of the registration is documented in the
registry as the consent date. Approved language by the Providence Privacy
Board and Institutional Review Board and in accordance with all HIPAA
regulations for implied consent is below: “If you agree to take part in this
project, please fill out the online registration form. Once we receive your
completed form as your consent to participate, we will send you surveys to
learn about you, your disease, and the medicines or services you use to help
manage your disease. Participation is voluntary and you will not receive
payment for participating.”
Taking part in the registry will have no effect on your relationship with your
doctors. The information that you and other persons with MS provide will be
used only for research purposes; for example, to compare the rate of MS
between different regions, or to compare the health care available to MS
patients living in rural versus urban areas.
“We will make every effort to protect your privacy. A number will be
assigned to represent your information. All information about you will be
kept in secure, locked cabinets and password-protected computer files. Your
personal identity will not be shown as part of any reports or made available
to insurance or other companies. We may send you additional surveys from
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time to time, but your privacy will always be protected. Only the MS Registry
researchers will have access to the information you provide for the registry.
You are not required to answer all survey questions. Also, you may choose
to stop your participation at any time. If you decide to stop taking part in
the MS registry, please notify us by using the Pacific Northwest MS Registry
contact information. Information that you have already provided will still be
used in the registry, but no more information about you will be collected. If
you have any questions about the registry please contact Dr. Stanley Cohan’s
office at 503–216-1060. If you have any questions about the use of your in-
formation for research purposes, please call the Providence Health & Services
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